LONDON, August 15, 2018 /PRNewswire/ -- Device fully automates neonatal Lung Maturity Test (LMT), representing a major milestone achievement and putting LMT on track for final clinical validation and commercialisation.  

SIME Dx, a digital molecular medicine company focused on the development and commercialisation of point-of-care (POC) diagnostics, today announced a new device design that fully automates the company's novel neonatal Lung Maturity Test (LMT). LMT, the first application on the patented Digital Molecular Diagnostics (DMDx) platform, has been clinically proven to predict Respiratory Distress Syndrome (RDS) with high accuracy. RDS is the leading cause of morbidity and mortality in premature babies, and can only be prevented with early diagnosis and targeted treatment.